Reset filter
Keywords
Medical Oncology ×
Mostra di più Keywords
Sommario
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

40 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Lung Cancer NCT02183870 DRKS00005409

- 7/7/17 - 1 modulo, 2 itemgroups, 35 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Prof. Dr. Juergen Wolf, Professor Dr. med., Leader of the LCGC, University of Cologne ClinicalTrials.gov Identifier: NCT02183870 History of Changes Other Study ID Numbers: EUCROSS 2013-002737-38 ( EudraCT Number ) DRKS00005409 ( Other Identifier: DRKS ) Study First Received: June 25, 2014 Last Updated: December 7, 2015 EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02183870

Eligibility Small Cell Lung Cancer NCT02038647 DRKS00007849

- 7/10/17 - 1 modulo, 2 itemgroups, 24 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Millennium Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02038647 History of Changes Other Study ID Numbers: C14018 2013-003713-18 ( EudraCT Number ) U1111-1154-9805 ( Registry Identifier: WHO ) DRKS00007849 ( Registry Identifier: DRKS ) Study First Received: December 4, 2013 Last Updated: March 30, 2017 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02038647

Eligibility Non-small-cell Lung Cancer NCT00442026

- 4/26/17 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT00442026

Eligibility Non-Small Cell Lung Cancer NCT00578149

- 4/26/17 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00578149

Eligibility Non-Small Cell Lung Cancer NCT00300729

- 4/25/17 - 1 modulo, 2 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00300729

Eligibility Non Small Cell Lung Cancer NCT00440414

- 4/25/17 - 1 modulo, 2 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00440414

Eligibility Non Small Cell Lung Cancer (NSCLC) NCT01210378

- 1/22/21 - 1 modulo, 1 ItemGroup, 17 elementi, 1 linguaggio
ItemGroup: Inclusion Criteria
Nitroglycerin in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01210378

Eligibility Carcinoma, Non-small Cell Lung NCT02511288

- 2/17/19 - 1 modulo, 4 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria, Exclusion Criteria
LIquid BIopsies in Lung Cancer (LIBIL); ODM derived from: https://clinicaltrials.gov/show/NCT02511288

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Non-Serious Adverse Event; Serious Adverse Events; Concomitant Medications

- 10/30/19 - 1 modulo, 15 itemgroups, 105 elementi, 1 linguaggio
Itemgroups: Non-Serious Adverse Event, Serious Adverse Event, SAE - Type of Report, SAE- Randomisation, SAE - Seriousness, SAE - Relevant Concomitant Medications, SAE - Relevant Medical Conditions/ Risk Factors, SAE - Relevant Diagnostic Results, SAE - Rechallenge, SAE - Investigational Product, SAE - Investigational Product, SAE - Investigational Product , SAE - General Narrative Comments, SAE - Non clinical, Concomitant Medications
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Liver Events; Investigational Product (Liver); Alcohol Intake (Liver Alcohol); Medical Conditions; Pharmacokinetics (Liver); Liver Biopsy; Liver Imaging

- 8/2/19 - 1 modulo, 10 itemgroups, 102 elementi, 1 linguaggio
Itemgroups: Liver Events, Investigational Product (Liver) , Alcohol intake, Medical Conditions (Liver), Drug related liver disease conditions, Other liver disease conditions, Other medical conditions, Pharmacokinetics (Liver PK), Liver Biopsy, Liver imaging
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Cancer and Non-Cancer related surgical Procedures; Investigational Product; Blood Products and Blood Supportive Care Products; Date of Visit/ Assessment; Unscheduled Lesion Assessment; Follow-Up; Follow-Up Anti-Cancer Therapy; Follow-Up Radiotherapy

- 5/29/19 - 1 modulo, 9 itemgroups, 54 elementi, 1 linguaggio
Itemgroups: Prior Cancer and Non-Cancer related surgical procedures, Investigational Product, Investigational Product - Dose Modifications, Blood Products and Blood Supportive Care Products, Date of visit/ Assessment, Unscheduled Lesion Assessment, Follow-Up, Follow-Up Anti-Cancer Therapy, Follow-Up Anti-Cancer Radiotherapy
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Death; Study Conclusion; Pharmacogenetic Research Withdrawal of Consent; Pregnancy Information; Investigatoinal Product Discontinuation; Investigational Product Compliance - Pazopanib; Log Status

- 5/23/19 - 1 modulo, 7 itemgroups, 26 elementi, 1 linguaggio
Itemgroups: Death, Study Conclusion, Pharmacogenetic Research Withdrawal of Consent, Pregnancy Information, Investigational Product Discontinuation, Investigational Product Compliance, Log Status
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial